Bettina M. Knoll, Sandro Vento, Zelalem Temesgen

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Etravirine, formerly known as TMC 125, is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent activity against HIV resistant to currently licensed NNRTIs. It is in its final stage of clinical development and has received fast-track status for review by the U.S. Food and Drug Administration (FDA). In randomized placebo-controlled trials in treatment-experienced patients with confirmed NNRTI resistance, it has shown virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are significant drug interaction issues that will need to be taken into consideration with its use.

Original languageEnglish (US)
Pages (from-to)23-33
Number of pages11
JournalDrugs of Today
Issue number1
StatePublished - Jan 2008

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Etravirine'. Together they form a unique fingerprint.

Cite this